Cholesteatoma of the Attic

Comprehensive Clinical Guide: Cholesteatoma of the Attic (Attic Cholesteatoma)

1. Introduction and Overview

Cholesteatoma of the attic, medically classified as a form of primary acquired cholesteatoma, represents a destructive, non-neoplastic, keratinizing squamous epithelial lesion occurring within the middle ear space. Specifically, it involves the epitympanum (the attic), the space located superior to the tympanic membrane. Despite its name, a cholesteatoma contains no cholesterol; it is essentially a "skin cyst" in the wrong location.

If left untreated, attic cholesteatomas are aggressively expansive. They possess the inherent capability to erode the delicate ossicular chain (malleus, incus, and stapes) and penetrate the bony boundaries of the temporal bone, potentially exposing the dura mater, facial nerve, or the lateral semicircular canal. Given its potential for intracranial complications, it is considered a surgical disease requiring definitive otological intervention.

2. Deep-Dive: Etiology and Pathophysiology

The Mechanism of Attic Retraction

The attic is a confined space. The primary mechanism for the development of an attic cholesteatoma is the formation of a pars flaccida retraction pocket.

• Eustachian Tube Dysfunction (ETD): Chronic negative pressure in the middle ear space exerts a vacuum effect on the tympanic membrane.
• The Pars Flaccida: Because the pars flaccida (Shrapnell’s membrane) is more compliant than the pars tensa, it is the first to retract inward toward the attic.
• Keratin Accumulation: As the pocket deepens, the natural migration of squamous epithelium is trapped. Instead of shedding into the ear canal, the keratin debris accumulates, forming a keratinaceous plug.
• Enzymatic Erosion: The trapped keratin serves as a nidus for infection. The surrounding subepithelial tissue (perimatrix) secretes cytokines and collagenases (such as IL-1, IL-6, and TNF-alpha) which stimulate osteoclasts, leading to the resorption of the surrounding bone.

Histological Composition

3. Clinical Indications and Presentation

Standard Clinical Presentation

Patients often present with a triad of symptoms, though early-stage disease may be asymptomatic.

1. Otorrhea: Persistent, foul-smelling discharge from the ear is the hallmark sign.
2. Conductive Hearing Loss: Occurs as the mass grows and interferes with the vibration of the ossicles.
3. Aural Fullness/Pressure: A sensation of blockage caused by the mass effect within the epitympanum.

Clinical Staging (EAONO/JOS Classification)

The European Academy of Otology and Neurotology (EAONO) and the Japan Otological Society (JOS) utilize a staging system based on the extent of the disease:

4. Diagnostic Evaluation

Key Diagnostic Tests

• Otoscopy/Micro-otoscopy: The gold standard for initial evaluation. Examination usually reveals a retraction pocket in the pars flaccida, often masked by a crust or debris.
• Audiometry: Pure-tone audiometry is essential to quantify the degree of conductive hearing loss and to assess the integrity of the ossicular chain.
• High-Resolution Computed Tomography (HRCT): The imaging modality of choice. It provides critical information regarding bony erosion (scutum erosion, ossicular destruction, and tegmen integrity).
• Magnetic Resonance Imaging (MRI) - Diffusion Weighted: Non-echo-planar imaging (DWI-EPI) is highly sensitive for detecting residual or recurrent cholesteatoma, as it can distinguish keratin from fluid/scar tissue.

Differential Diagnosis

It is vital to distinguish attic cholesteatoma from:
* Chronic Suppurative Otitis Media (CSOM): Usually involves the pars tensa.
* External Auditory Canal Cholesteatoma: Occurs primarily in the canal, not the middle ear.
* Cholesterol Granuloma: Often associated with dark "blue-black" appearance behind an intact drum.
* Glomus Tympanicum: A vascular tumor that presents as a pulsatile red mass.

5. Risks, Side Effects, and Complications

The risks of untreated attic cholesteatoma are profound. The "silent" nature of the disease often leads to delayed diagnosis.

• Ossicular Chain Erosion: Specifically the long process of the incus, leading to permanent conductive hearing loss.
• Facial Nerve Paralysis: Erosion of the Fallopian canal.
• Sensorineural Hearing Loss: Caused by fistula formation in the lateral semicircular canal (labyrinthine fistula).
• Intracranial Complications:
  • Meningitis.
  • Brain abscess (temporal lobe or cerebellar).
  • Sigmoid sinus thrombosis.

6. Surgical Management

Surgery is the only definitive treatment. The goal is to create a "safe" ear (one that is dry and free of disease) and, if possible, restore hearing.

1. Canal Wall Up (CWU) Mastoidectomy: Preserves the posterior canal wall but carries a higher risk of recurrence.
2. Canal Wall Down (CWD) Mastoidectomy: Removes the canal wall to ensure complete visualization and removal of the matrix; lower recurrence, but requires long-term mastoid cavity care.
3. Tympanoplasty: Reconstruction of the tympanic membrane and ossicular chain (ossiculoplasty).

7. Frequently Asked Questions (FAQ)

1. Is attic cholesteatoma a type of cancer?
No. It is a benign, non-neoplastic growth. However, it is considered "locally aggressive" because it destroys surrounding bone and tissue.

2. Can antibiotic ear drops cure a cholesteatoma?
No. Antibiotics can treat secondary infections and reduce drainage, but they cannot remove the keratin mass or the epithelial matrix. Surgical removal is mandatory.

3. Will my hearing return to normal after surgery?
Often, hearing can be improved, but it depends on the severity of the ossicular damage. In some cases, a second-look surgery is required to reconstruct the hearing mechanism.

4. How long does the surgery take?
Depending on the extent of the disease, the procedure typically lasts between 2 to 4 hours.

5. Is the surgery performed under local or general anesthesia?
General anesthesia is standard for ear surgery to ensure patient safety and immobilization.

6. What is the likelihood of recurrence?
Recurrence rates vary based on surgical technique and the extent of the initial disease. Modern techniques report recurrence rates of 10–20%.

7. How often do I need to follow up?
Lifetime follow-up is recommended. Initially, follow-ups are frequent (every 3–6 months) to ensure the ear remains dry and free of recurrence.

8. Can I go swimming after surgery?
Patients must avoid getting water in the affected ear until the surgeon confirms the ear is fully healed, which may take several months. Waterproof ear protection is often required long-term.

9. What are the warning signs of a complication?
Severe vertigo, sudden onset of facial weakness, high fever, or severe headache must be reported to the surgeon immediately.

10. Why is CT imaging so important?
CT scans allow the surgeon to map the anatomy of the disease, identifying precisely which bony structures have been eroded, which guides the surgical approach.

8. Prognosis and Long-Term Outlook

The prognosis for patients with attic cholesteatoma is generally favorable provided the disease is identified early and managed by a fellowship-trained otologist/neurotologist. While the disease is chronic in nature, modern surgical techniques—combined with advanced imaging like Diffusion-Weighted MRI—have significantly improved the ability to monitor and manage the condition, effectively reducing the incidence of catastrophic intracranial complications.

Successful management requires a partnership between the patient and the surgical team. Long-term surveillance is the cornerstone of preventing recurrence and maintaining an "attic-safe" ear. Patients should be counseled that while the cholesteatoma itself can be removed, the underlying Eustachian tube dysfunction that precipitated the condition may persist, necessitating vigilance for the remainder of the patient's life.